ECSP088778A - FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY - Google Patents

FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Info

Publication number
ECSP088778A
ECSP088778A EC2008008778A ECSP088778A ECSP088778A EC SP088778 A ECSP088778 A EC SP088778A EC 2008008778 A EC2008008778 A EC 2008008778A EC SP088778 A ECSP088778 A EC SP088778A EC SP088778 A ECSP088778 A EC SP088778A
Authority
EC
Ecuador
Prior art keywords
igf
monoclonal antibody
formulation
human monoclonal
preparation
Prior art date
Application number
EC2008008778A
Other languages
Spanish (es)
Inventor
Hanns-Christian Mahler
Adelbert Grossmann
Jan Stracke
Astrid Pappenberger
Oliver Boris Stauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088778A publication Critical patent/ECSP088778A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está relacionada con una formulación de anticuerpo monoclonal humano anti-IGF-1R, un proceso para la preparación y usos del mismo.The present invention is related to an anti-IGF-1R human monoclonal antibody formulation, a process for the preparation and uses thereof.

EC2008008778A 2006-03-28 2008-09-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY ECSP088778A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
ECSP088778A true ECSP088778A (en) 2008-10-31

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008778A ECSP088778A (en) 2006-03-28 2008-09-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Country Status (18)

Country Link
EP (1) EP1998806A1 (en)
JP (1) JP2009531371A (en)
KR (1) KR20080104160A (en)
CN (1) CN101410137A (en)
AR (1) AR060130A1 (en)
AU (1) AU2007229554A1 (en)
BR (1) BRPI0709229A2 (en)
CA (1) CA2647111A1 (en)
CL (1) CL2007000797A1 (en)
CR (1) CR10295A (en)
EC (1) ECSP088778A (en)
IL (1) IL193904A0 (en)
MA (1) MA30345B1 (en)
MX (1) MX2008012295A (en)
NO (1) NO20083895L (en)
RU (1) RU2008142359A (en)
TW (1) TW200815029A (en)
WO (1) WO2007110339A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007003583A1 (en) * 2006-12-11 2008-07-18 Hoffmann La Roche STABLE, PARENTERAL PHARMACEUTICAL FORMULATION OF THE ANTIBODY AGAINST THE BETA AMYLOID PEPTIDE (ABETA); AND USE OF THE FORMULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc Stable antibody formulations
EP2167127A1 (en) * 2007-07-10 2010-03-31 F. Hoffmann-Roche AG Novel formulation
US20100249384A1 (en) * 2007-11-29 2010-09-30 Stefan Hepbildikler Immunoglobulin aggregates
BRPI0820819B1 (en) * 2007-12-21 2021-06-08 F. Hoffmann-La Roche Ag b-ly 1 humanized antibody formulation and its use
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
BR112012013148A2 (en) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag pharmaceutical formulation and use
RU2012153786A (en) * 2010-05-28 2014-07-10 Ново Нордиск А/С STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT
PT2691112T (en) 2011-03-31 2018-07-10 Merck Sharp & Dohme Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN102363040B (en) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 Antimicrobial peptide preparation for mucosal tissues
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
UA118029C2 (en) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг MODIFIED ANTIBODY TO CONTACT HUMAN FCRN AND METHODS OF ITS APPLICATION
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
CN103505729B (en) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 A kind of stable rabies virus human antibody combination preparation
CN104707146B (en) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 A pharmaceutical composition containing adalimumab
MX380658B (en) 2014-01-15 2025-03-11 Hoffmann La Roche REGION FC VARIANTS WITH ENHANCED PROTEIN A BINDING.
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
AR102198A1 (en) 2014-10-09 2017-02-08 Regeneron Pharma PROCESS TO REDUCE SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
HUE057952T2 (en) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transferrin receptor antibodies with customized affinity
CN106999591B (en) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 anti-PD-1 antibody preparation and application thereof in medicine
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
TWI873952B (en) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
JP7102401B2 (en) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods and systems for chromatographic data analysis
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP7382232B2 (en) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー Preparation of anti-LAG3 antibody and co-formulation of anti-LAG3 antibody and anti-PD-1 antibody
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
TWI853823B (en) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 Systems and methods for preparing a polypeptide from a mixture
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (en) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Anti-human pd-1 antibody crystals and methods of use thereof.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
EA202192422A1 (en) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. HUMAN SERUM ALBUMIN IN COMPOSITIONS
CN114324882B (en) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 Protein stabilizer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635352C (en) * 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
ME00502B (en) * 2001-01-05 2011-10-10 Amgen Fremont Inc Antibodies to insulin-like growth factor i receptor
MXPA04000747A (en) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Stable lyophilized pharmaceutical formulation of igg antibodies.
ES2383014T3 (en) * 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor I and their uses
MXPA05010555A (en) * 2003-04-04 2006-03-09 Genentech Inc High concentration antibody and protein formulations.
AR046071A1 (en) * 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
DE602004029581D1 (en) * 2003-08-13 2010-11-25 Pfizer Prod Inc MODIFIED HUMANESE IGF-1R ANTIBODIES

Also Published As

Publication number Publication date
IL193904A0 (en) 2011-08-01
AR060130A1 (en) 2008-05-28
NO20083895L (en) 2008-10-24
CN101410137A (en) 2009-04-15
CR10295A (en) 2008-10-06
CL2007000797A1 (en) 2008-01-25
RU2008142359A (en) 2010-05-10
EP1998806A1 (en) 2008-12-10
BRPI0709229A2 (en) 2011-06-28
MX2008012295A (en) 2008-10-09
JP2009531371A (en) 2009-09-03
TW200815029A (en) 2008-04-01
MA30345B1 (en) 2009-04-01
CA2647111A1 (en) 2007-10-04
WO2007110339A1 (en) 2007-10-04
KR20080104160A (en) 2008-12-01
AU2007229554A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
ECSP088778A (en) FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY
ECSP10010295A (en) FORMULATION OF ANTIBODY
MX353706B (en) ANTIBODIES AGAINST HUMAN CSF-1R AND USES OF THE SAME.
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
CR20160355A (en) NEUTRALIZING ANTIBODIES OF HUMAN ATOMEGALOVIRUS AND USE OF THE SAME
CR20120310A (en) NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR AND THERAPEUTIC USE
EA200900040A1 (en) ANTIBODY MOLECULES THAT ASSOCIATE WITH HUMAN IL-17
CY1117563T1 (en) HER3 PARTS AND USE OF THESE
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
CO6420355A2 (en) ANTI-ERBB-3 / ANTI-C-MET ANTI-ERBB ANTIBODIES
BRPI1014544B8 (en) isolated fully human monoclonal anti-il-17f antibody and pharmaceutical composition comprising the same
CR20150625A (en) COMPOSITION UNDERSTANDING ANTIBODY FIXED TO DOMAIN II OF HER2 AND ITS VARIOUS ACIDS
MX353827B (en) Forms of rifaximin and uses thereof.
CO7151488A2 (en) Anti-jagged1 / jagged 2 cross-reaction antibodies, activatable anti-jagged antibodies and methods of use thereof
GT201200318A (en) ANTIBODIES TO GDF8 HUMAN
CR20110204A (en) IMPROVED ANTIBODY MOLECULES
CO6362023A2 (en) ANTI-EGFR / ANTI-IGF-1R BIESPECIFIC ANTIBODIES
ECSP13012877A (en) SOLID FORMS SDE 3- (5-AMINO-2-methyl -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, AND ITS PHARMACEUTICAL COMPOSITIONS AND USES
LT2013015A (en) PHARMACEUTICAL COMPOSITIONS
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
CR10561A (en) VACCINES FOR MALARIA
MX2016000794A (en) High potency pancreatin pharmaceutical compositions.
EA201200616A1 (en) DERIVATIVES 2-OXO-1-PIRROLIDININILIMIDAZOTHIAADIA ASOL
ES2524385R1 (en) Pharmaceutical composition and its use to prepare a medicine for the treatment and prevention of HIV diseases
MX349235B (en) Monoclonal antibodies specific for the m2-1 antigen of respiratory syncytial virus (rsv).